Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Overnight DNA test could speed up cancer care for kids

NCT ID NCT07201038

Knowledge-focused Sponsor: University of Cambridge Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a new, ultrafast whole genome sequencing test can give doctors genetic information about a child's cancer within days instead of the usual 1-4 weeks. Researchers at Cambridge University Hospitals will enroll 50 children and young adults under 25 with suspected or confirmed cancer. The goal is to see if faster results can help guide treatment decisions sooner, especially for high-risk cancers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ultrafast whole genome sequencing (WGS)
What this could lead to
If successful, this could replace slower genetic tests, allowing doctors to identify high-risk cancers and start targeted treatments within days instead of weeks.
What could go wrong
This is a small feasibility study with only 50 participants, so results may not apply to all children. The technology may not be fast or reliable enough in routine practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2022

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Children with cancer at relapse or initial diagnosis

Ages

0 to 24 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have given written informed consent to participate * Be aged \<25 years of age * Have confirmed or suspected malignancy * For pilot/feasibility study (first 10 patients), only haematological malignancies (ALL/AML) will be included * Have tumour and germline sample available - retrospectively collected or for prospective collection Exclusion Criteria: * Inability to provide written informed consent (self or parent/guardian) * Insufficient tissue (BM/PB/tissue) available for research purposes after collection for routine diagnostic purposes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer childhood are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

childhood malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer childhood

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Addenbrookes Hospital

    RECRUITING

    Cambridge, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.